Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Essa Pharma (EPIX)

Essa Pharma (EPIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 283,480
  • Shares Outstanding, K 44,363
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,580 K
  • 60-Month Beta 1.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.12
Trade EPIX with:

Options Overview Details

View History
  • Implied Volatility 94.24% ( -99.95%)
  • Historical Volatility 60.13%
  • IV Percentile 9%
  • IV Rank 13.02%
  • IV High 496.99% on 10/16/23
  • IV Low 33.93% on 06/12/23
  • Put/Call Vol Ratio 0.10
  • Today's Volume 11
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 672
  • Open Int (30-Day) 694

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.15
  • Low Estimate -0.28
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.52 +13.58%
on 05/20/24
7.33 -14.47%
on 05/03/24
+0.19 (+3.13%)
since 04/26/24
3-Month
5.52 +13.58%
on 05/20/24
9.92 -36.79%
on 03/01/24
-2.53 (-28.75%)
since 02/28/24
52-Week
2.58 +143.02%
on 09/14/23
11.67 -46.27%
on 02/07/24
+3.24 (+106.93%)
since 05/26/23

Most Recent Stories

More News
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...

EPIX : 6.27 (-1.88%)
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 6.27 (-1.88%)
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

/CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 6.27 (-1.88%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 6.27 (-1.88%)
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 6.27 (-1.88%)
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose...

EPIX : 6.27 (-1.88%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the...

EPIX : 6.27 (-1.88%)
U.S. CPI, Fed Decision in News Next Wee

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q2) Reported EPS for $1.05, ...

TCL-A.TO : 13.43 (+0.60%)
DOL.TO : 122.80 (-1.07%)
ORCL : 124.49 (+1.29%)
CASY : 337.32 (-1.70%)
BLBD : 55.20 (+1.21%)
JCI : 72.68 (-1.65%)
PLAB : 27.29 (+3.45%)
EPIX : 6.27 (-1.88%)
ADBE : 478.43 (+0.63%)
LEN : 154.95 (-0.91%)
NDSN : 233.58 (-1.83%)
COST : 813.17 (+0.42%)
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 6.27 (-1.88%)
ESSA Pharma to Present at the Jefferies London Healthcare Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 6.27 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 7.03
2nd Resistance Point 6.69
1st Resistance Point 6.48
Last Price 6.27
1st Support Level 5.93
2nd Support Level 5.59
3rd Support Level 5.38

See More

52-Week High 11.67
Fibonacci 61.8% 8.20
Fibonacci 50% 7.13
Last Price 6.27
Fibonacci 38.2% 6.05
52-Week Low 2.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar